The combination of two immunotherapies for first-line treatment of advanced melanoma induces better responses and far longer progression-free survival than giving one of those drugs alone, new research shows. Further, the combination was effective in the portion of melanoma patients--the majority--who currently have few effective treatment options.
from Latest Science News -- ScienceDaily http://ift.tt/1GaPri1 via
Karis World
No comments:
Post a Comment